SCHEMBL13895439

SCHEMBL13895439

CCN1CCCC1C(=O)C(C)C

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 1/20 0.45
HTT P42858 1/20 0.42
KMT2A Q03164 2/20 0.41
MEN1 O00255 1/20 0.41
ALDH1A1 P00352 1/20 0.41
ACE P12821 6/20 0.38
REN P00797 3/20 0.38
KDM4E B2RXH2 1/20 0.38
F2 P00734 1/20 0.38
LMNA P02545 1/20 0.38
LTA4H P09960 1/20 0.38
MAPT P10636 1/20 0.38
PEPD P12955 1/20 0.38
ALOX15 P16050 1/20 0.38
PTGS1 P23219 1/20 0.38
HTR2A P28223 1/20 0.38
PTGS2 P35354 1/20 0.38
HRH1 P35367 1/20 0.38
THPO P40225 1/20 0.38
PMP22 Q01453 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23960424 1.00 L3MBTL1 (0.45) L3MBTL1HTTKMT2AMEN1ALDH1A1
SCHEMBL23408423 0.87 L3MBTL1 (0.40) L3MBTL1HTTKMT2AMEN1ACE
SCHEMBL22919270 0.83 L3MBTL1 (0.41) L3MBTL1HTTKMT2AMEN1ALDH1A1
SCHEMBL19130471 0.80 S1PR1 (0.48)
SCHEMBL28083515 0.80 ALDH1A1 (0.45) L3MBTL1HTTALDH1A1ACEREN
SCHEMBL12110041 0.79 L3MBTL1 (0.54) L3MBTL1HTTKMT2AMEN1ALDH1A1
SCHEMBL14454197 0.79 L3MBTL1 (0.54) L3MBTL1HTTKMT2AMEN1ALDH1A1
SCHEMBL13244098 0.79 ALDH1A1 (0.44) L3MBTL1HTTALDH1A1ACEREN
SCHEMBL15200247 0.79 ALDH1A1 (0.44) L3MBTL1HTTALDH1A1ACEREN
SCHEMBL13347926 0.79 ALDH1A1 (0.44) L3MBTL1HTTALDH1A1ACEREN

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240218365-A1 FORMULATION OF AN ANTISENSE OLIGOMER CONJUGATE THE PROGERIA RESEARCH FOUNDATION, INC. 2024-07-04 US disclosed
EP-4306538-A2 PEPTIDE OLIGONUCLEOTIDE CONJUGATES Sarepta Therapeutics, Inc. (US) 2024-01-17 EP disclosed
US-11672871-B2 Peptide oligonucleotide conjugates SAREPTA THERAPEUTICS, INC. (US) 2023-06-13 US disclosed
US-20230018246-A1 PYRROLIDINE CARBOXAMIDO DERIVATIVES AND METHODS FOR PREPARING AND USING THE SAME Research & Business Foundation Sungkyunkwan University (KR) 2023-01-19 US disclosed
WO-2021217019-A1 RAS INHIBITORS AND USES THEREOF THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2021-10-28 WO disclosed
US-10675356-B2 Peptide oligonucleotide conjugates SAREPTA THERAPEUTICS, INC. (US) 2020-06-09 US disclosed
US-20180214567-A1 Peptide Oligonucleotide Conjugates SAREPTA THERAPEUTICS, INC. (US) 2018-08-02 US disclosed
WO-2012148550-A1 PRODRUGS OF THERAPEUTIC COMPOUNDS MYREXIS, INC. (US) 2012-11-01 WO disclosed
US-7332489-B2 Methods and compositions of novel triazine compounds REDDY US THERAPEUTICS, INC. (US) 2008-02-19 US disclosed
US-7332488-B2 Methods and compositions of novel triazine compounds REDDY US THERAPEUTICS, INC. (US) 2008-02-19 US disclosed
US-7238692-B2 Medical devices employing triazine compounds and compositions thereof REDDY US THERAPEUTICS, INC. (US) 2007-07-03 US disclosed
US-20070117795-A1 Methods and compositions of novel triazine compounds DR. REDDY'S LABORATORIES LTD. (IN) 2007-05-24 US disclosed
US-20070099874-A1 Methods and compositions of novel triazine compounds REDDY US THERAPEUTICS, INC. (US) 2007-05-03 US disclosed
US-7169785-B2 Methods and compositions of novel triazine compounds REDDY US THERAPEUTICS, INC. (US) 2007-01-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070099874-A1 Methods and compositions of novel triazine compounds AREG, TGFB1, PTGIS L3MBTL1 4810/4885HTT 805/4885KMT2A 4102/4885
US-20180214567-A1 Peptide Oligonucleotide Conjugates MYOF, MUSK, MTPN L3MBTL1 133/4885HTT 1426/4885KMT2A 4025/4885
US-10675356-B2 Peptide oligonucleotide conjugates MYOF, MUSK, MTPN L3MBTL1 133/4885HTT 1426/4885KMT2A 4025/4885
US-11672871-B2 Peptide oligonucleotide conjugates MYOF, MUSK, MTPN L3MBTL1 133/4885HTT 1426/4885KMT2A 4025/4885
US-20240218365-A1 FORMULATION OF AN ANTISENSE OLIGOMER CONJUGATE POLB, GBA1, POLN L3MBTL1 914/4885HTT 85/4885KMT2A 2841/4885
US-20230018246-A1 PYRROLIDINE CARBOXAMIDO DERIVATIVES AND METHODS FOR PREPARING AND USING THE SAME NOD2, SI, APC L3MBTL1 4821/4885HTT 1038/4885KMT2A 3249/4885
US-20070117795-A1 Methods and compositions of novel triazine compounds AREG, TGFB1, PTGIS L3MBTL1 4810/4885HTT 805/4885KMT2A 4102/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.